What is the best time to take Plavix? (3+ points to ensure safe and effective use)
By
Dr Natalia Marceli Stephanes (PhD)
Author bio
Dr Natália Marcéli Stephanes PhD is a Pharmacist with expertise in Drugs Administration and Toxicity; Discovery of New Drugs; Cancer Treatment; Biochemical Analyzes and Hematological Analyzes. She writes and reviews content on these topics.
Dr Natália Marcéli Stephanes’ Highlights:
- Pharmacist at the Department of Health of Santa Catarina State, Brazil
- PhD with a focus on oncology treatment
- Years of experience in commercial pharmacy
- Bachelor, Master and PhD degrees in Pharmacy at the Federal University of Santa Catarina
Professional Experience:
From her undergraduate studies to her Master’s and Doctorate degrees in Pharmacy, Dr Natália Marcéli Stephanes has participated in numerous scientific studies in the field of oncology and onco-hematology at the University Hospital of the Federal University of Santa Catarina, Brazil. Her research has focused on understanding the molecular and biochemical bases of malignant neoplasms and investigating safer and more effective therapeutic alternatives.
Dr Natália Marcéli Stephanes has also served as an assistant professor of haematology for undergraduate students at the Federal University of Santa Catarina. Additionally, she held the position of professor of Hospital Pharmacy at the Qualificar Technical School in Brazil, where she developed instructional materials for use in the Pharmacy Postgraduate Program at the Leonardo Da Vinci University Center.
In addition to her academic experiences, Dr Natália Marcéli Stephanes possesses a strong expertise in commercial pharmacy, with in-depth knowledge of medications, their routes of administration, desired effects, adverse effects, and toxicity.
Currently, Dr Natália Marcéli Stephanes works as a Pharmacist at the Health Department of Santa Catarina State, where her role entails providing pharmaceutical scientific consulting services to judges.
Education:
- 2016 Bachelor in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2018 Master in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2023 PhD in Pharmacy at the Federal University of Santa Catarina, Brazil
The main publications of Dr Natália Marcéli Stephanes are:
Falchetti M ; Delgobo M, Zancanaro H, Almeida K, Das Neves RN, Dos Santos B, Stefanes NM, et al. Bishop Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. Comput. Biol. Med [Internet]. 2023; 152:106347.
Feuser PM, Matos dos Santos PC, Cordeiro AP, Stefanes NM, Walter LO, Maioral MF, Santos-Silva MC, et al. Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). J Drug Deliv Sci Technol [Internet]. 2022; 67:102924.
Jacques AV, Stefanes NM, Walter LO, Perondi DM, Efe FL, Souza LFS, Sens L, et al. Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines. Bioorg. Chem [Internet]. 2021; 116:105315.
Duarte BF, Vieira DSC, Lisboa ML, Stefanes NM, Grando LJ, Santos-Silva MC. Características clínico-epidemiológicas de pacientes portadores de carcinoma de células escamosas de boca. Arquivos Catarinenses de Medicina. 2021; 50(2): 232–245.
Machado V, Jacques AV, Stefanes NM, Santos-Silva MC, Biavatti MW. Anti-leukemic activity of semisynthetic derivatives of Lupeol. Nat. Prod. Res. 2021; 35(22):4494-4501.
Bigolin A, Maioral MF, Stefanes NM, Mascarello A, Chiaradia-Delatorre LD, Nunes RJ, Yunes RA, et al. A novel sulfonamide derivative as a strong and selective apoptotic agent against hematological malignancies. Chem. Pap. 2020; 74:2965–2976.
Bigolin A, Maioral MF, Stefanes NM, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Anticancer Drugs. 2020; 31(7):709-717.
Maioral MF, Stefanes NM, Neufeldt PD, Chiaradia-Delatorre LD, Nunes RJ, Santos-Silva MC. Aldehyde biphenyl chalcones induce immunogenic apoptotic-like cell death and are promising new safe compounds against a wide range of hematologic cancers. Future Med. Chem. 2020; 12(8):673–688.
Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, Cury NM, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs. 2019; 30(8):p 828-837.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Argenta DF, Dotto MER, Santos-Silva MC, et al. PEO-chitosan nanofibers containing carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanoparticles loaded with pyrazoline for skin cancer treatment. Eur. Polym. J. 2019; 119:335-343.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Santos-Silva MC, Nunes RJ, Parize AL, et al. A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity. Mater. Sci. Eng. C [Internet]. 2019; 105:110051.
Maioral MF, Stefanes NM, Bigolin A, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Miconidine acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells. Invest. New Drugs. 2019; 37:912–922.
Srefanes NM, Toigo J, Maioral MF, Jacques AV, Chiaradia-Delatorre LD, Perondi DM, Ribeiro AAB, et al. Synthesis of novel pyrazoline derivatives and the evaluation of death mechanisms involved in their antileukemic activity. Bioorg. Med. Chem. 2019; 27(2):375-382.
Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochim. 2017; 140:48-57.
You can view some of Dr Natália’s work below and links to her professional profile below.
Research Gate: https://www.researchgate.net/profile/Natalia-Stephanes
Linkedin: https://www.linkedin.com/in/nataliamarceli/
This article will discuss the best time of taking Plavix, a blood-thinning medication. We will also talk about the dosing schedule of this medication and what factors are important to consider before taking Plavix. We will also discuss some points for ensuring safe and effective use.
What is the best time to take Plavix?
Plavix (Clopidogrel) can be taken at any time of the day (1). There is no specific time restriction for this medication and you can take it whenever it is convenient for you. However, it is important to make sure that you take it at the exact same time each day.
Plavix is usually taken once daily. Most people take it in the morning, with or without food. The timing can differ from person to person. It’s important to follow your doctor’s directions and take it when your doctor has advised you to.
It’s also important to maintain a consistent level of Plavix in your body. This can help ensure the effectiveness of the medication.
What are the dosage recommendations for Plavix?
The typical dose of Plavix is 75 milligrams taken once daily. In some cases, the doctor might prescribe a higher, one-time dose of Plavix, such as 300mg or 600mg. (2)(3)
This is not a usual daily dose but a specific dosage that your doctor will determine based on your medical needs.
In some cases, Plavix may be used in a combined form with another blood thinner, like Aspirin. A combination of 75mg of Clopigodrel and 75mg of Aspirin is available under the brand name ‘CoPlavix’.
However, both of these versions are available on prescription and should never be taken without your doctor’s prescription.
What factors are important to consider before taking Plavix?
There are some important factors to consider before taking Plavix (1)(2):
- Plavix might not be safe for everyone, so make sure your doctor has your full medical history before you start taking this medication.
- Inform your doctor if you’re allergic to Plavix or any other blood thinner.
- If you’ve had recent surgery or injury, it’s important to inform your doctor.
- If you’re pregnant. planning to become pregnant, or breastfeeding, discuss this with your doctor before taking Plavix.
How to ensure the safe and effective use of Plavix?
The following points are important to ensure the safe and effective use of Plavix: (1)
- Take Plavix exactly as prescribed by your doctor.
- Take it at the same time each day to maintain the concentration of the drug in your body.
- You can take it with or without food.
- Do not take more than the recommended dose or combine it with any medication without consulting your doctor first.
- Avoid the excessive use of alcohol while taking Plavix or other blood thinners. Alcohol should be completely avoided if you have liver disease or a bleeding disorder.
- Inform your doctor about all the supplements you’re taking.
- Properly monitor your response to Plavix and keep an eye out for potential side effects.
- If you forget to take your dose, take it as soon as you remember. If a lot of time has passed and your next dose is just around the corner, skip the missed dose and take the next one on time.
- In case you have accidentally overdosed on the medication, seek medical attention right away.
Remember, it’s important to ensure the safe and effective use of Plavix to achieve your desired therapeutic response. If you have any questions, you can always ask your doctor. It is not advisable to make any changes to your prescription without consulting your doctor first.
Conclusion
In this article, we have discussed the best possible time to take Plavix, a blood thinner. We have also discussed some important factors to consider before taking Plavix and some points to ensure its safe and effective use.
Was this helpful?
References
1.-
LABEL: PLAVIX- clopidogrel tablet, film coated. DailyMed [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=de8b0b67-eb25-4684-83b5-7ad785314227&type=pdf
2.-
The Food and Drug Administration (FDA). HIGHLIGHTS OF PRESCRIBING INFORMATION. PLAVIX® (clopidogrel bisulfate) tablets, for oral use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020839s070lbl.pdf
3.-
National Health Service. Clopidogrel: an antiplatelet medicine to prevent blood clots. London: National Health Service (NHS). Available from: https://www.nhs.uk/medicines/clopidogrel/
